A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
Latest Information Update: 10 Jul 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms LIBERTY-UC SUCCEED
- Sponsors Sanofi
Most Recent Events
- 20 May 2025 Planned End Date changed from 20 Feb 2026 to 24 Mar 2027.
- 20 May 2025 Planned primary completion date changed from 16 May 2025 to 17 Jun 2026.
- 12 Jun 2024 Planned number of patients changed from 100 to 84.